EE300 Cost Effectiveness of Momelotinib Vs Other Treatments for Myelofibrosis from a US Payer Perspective
| Autor: | Liu, T, Purser, M, Gong, C, Elsea, D, Niehoff, N, Dlotko, E, Migliaccio-Walle, K., Samyshkin, Y |
|---|---|
| Zdroj: | In Value in Health June 2024 27(6) Supplement:S112-S112 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect